EP0865298A1 - Drug therapy - Google Patents

Drug therapy

Info

Publication number
EP0865298A1
EP0865298A1 EP19960940685 EP96940685A EP0865298A1 EP 0865298 A1 EP0865298 A1 EP 0865298A1 EP 19960940685 EP19960940685 EP 19960940685 EP 96940685 A EP96940685 A EP 96940685A EP 0865298 A1 EP0865298 A1 EP 0865298A1
Authority
EP
Grant status
Application
Patent type
Prior art keywords
substance
system according
molecule
nh
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19960940685
Other languages
German (de)
English (en)
French (fr)
Inventor
Tariq Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzacta R and D Ltd
Original Assignee
AEPACT Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/04Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom
EP19960940685 1995-12-06 1996-12-06 Drug therapy Withdrawn EP0865298A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9524942 1995-12-06
GB9524942A GB9524942D0 (en) 1995-12-06 1995-12-06 Drug therapy
PCT/GB1996/003000 WO1997020580A1 (en) 1995-12-06 1996-12-06 Drug therapy

Publications (1)

Publication Number Publication Date
EP0865298A1 true true EP0865298A1 (en) 1998-09-23

Family

ID=10784998

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19960940685 Withdrawn EP0865298A1 (en) 1995-12-06 1996-12-06 Drug therapy

Country Status (5)

Country Link
EP (1) EP0865298A1 (it)
JP (1) JP2000502071A (it)
CA (1) CA2239203A1 (it)
GB (1) GB9524942D0 (it)
WO (1) WO1997020580A1 (it)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JP4616991B2 (ja) * 1998-09-18 2011-01-19 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
WO2000024426A1 (en) * 1998-10-23 2000-05-04 Intelligene Ltd. Ribozymes used as prodrugs
GB0916749D0 (en) * 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9720580A1 *

Also Published As

Publication number Publication date Type
JP2000502071A (ja) 2000-02-22 application
GB9524942D0 (en) 1996-02-07 grant
WO1997020580A1 (en) 1997-06-12 application
CA2239203A1 (en) 1997-06-12 application

Similar Documents

Publication Publication Date Title
Han et al. Targeted prodrug design to optimize drug delivery
Ettmayer et al. Lessons learned from marketed and investigational prodrugs
US5349066A (en) Bifunctional linking compounds, conjugates and methods for their production
US7223837B2 (en) Elongated and multiple spacers in activatible prodrugs
US6214345B1 (en) Lysosomal enzyme-cleavable antitumor drug conjugates
US7091186B2 (en) p-Amidobenzylethers in drug delivery agents
US6759509B1 (en) Branched peptide linkers
Dubowchik et al. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
EP0302473A2 (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5028697A (en) Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US20080279868A1 (en) Antibody-Drug Conjugates and Methods of Use
US4937183A (en) Method for the preparation of antibody-fragment conjugates
US5505931A (en) Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0328147A2 (en) Anthracycline immunoconjugates having a novel linker and methods for their production
Niculescu-Duvaz et al. Antibody-directed enzyme prodrug therapy (ADEPT): a review
US5639879A (en) Macrocyclic polyaminocarboxylates for stable radiometal antibody conjugates for therapy, spect and pet imaging
US7705045B2 (en) Prodrugs built as multiple self-elimination-release spacers
US5686578A (en) Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US7527787B2 (en) Multivalent immunoglobulin-based bioactive assemblies
US7521056B2 (en) Stably tethered structures of defined compositions with multiple functions or binding specificities
US7011812B1 (en) Targeted combination immunotherapy of cancer and infectious diseases
Deonarain et al. Targeting enzymes for cancer therapy: old enzymes in new roles
US20090246211A1 (en) Molecular constructs suitable for targeted conjugates
US20040259768A1 (en) Targeted release
Senter et al. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 19980514

AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Transfer of rights of an ep published application

Owner name: ENZACTA R & D LIMITED

17Q First examination report

Effective date: 20020424

18D Deemed to be withdrawn

Effective date: 20020905